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CORRESPONDENCE
Tumor Necrosis Factor–a Increased Production
during Thalidomide Treatment in Patients
with Tuberculosis and Human Immunodeficiency
Virus Coinfection
To the Editor—We read with interest the article by Bekker et
al. [1] on the role of thalidomide-induced antigen-specific im-
mune stimulation in patients with human immunodeficiency
virus (HIV) and Mycobacterium tuberculosis coinfection. In
their report, it is suggested that thalidomide treatment of HIV-
infected patients does not reduce plasma tumor necrosis factor
(TNF)–a levels. The observation is explained by a differential
effect of thalidomide on monocyte and T cell TNF-a pro-
duction. In particular, the authors report that thalidomide
inhibited TNF-a production by lipopolysaccharide-stimu-
lated monocytes but failed to inhibit TNF-a production by
activated T cells [2–5]. Finally, the authors found an increase
in TNF-a production at day 21 of therapy in the thalidomide
group, thus suggesting that the drug could be responsible for
this increase by stimulation of T cell activation.
As Bekker et al. observed, these data seem to be in contrast
with the findings of previous studies, mainly performed in
vitro, which reported an anti-inflammatory effect of thalid-
omide, mediated by an inhibition of TNF-a production [4,
6]. Nevertheless, the data confirm the most recent in vivo
reports showing an increase in TNF-a concentrations and
soluble TNF-a receptors during thalidomide treatment [7, 8].
These data suggest that thalidomide is not a systemic TNF-
a inhibitor. Moreover, it must be underlined that increased
TNF-a production in the thalidomide-treated patients was
associated with unexplained deaths when thalidomide was
used in the treatment of toxic epidermal necrolysis [7].
We conducted a study, similar to the one performed by
Bekker and colleagues, using thalidomide to treat HIV- and
tuberculosis-coinfected patients. We studied 6 HIV- and M.
tuberculosis–infected patients, characterized by a poor re-
sponse to the antituberculosis treatment, who were subse-
quently treated with thalidomide as adjuvant therapy. Im-
munological evaluations prior to thalidomide introduction
suggested that these patients had significantly lower levels of
TNF-a production than did the control subjects. Following
thalidomide treatment, we observed a progressive increase in
TNF-a production with a peak after about day 35 of therapy,
thus confirming the observations made by Bekker and col-
leagues [1]. The increase in TNF-a concurred with a signifi-
cant recovery of Th1 cytokine production, such as interleukin-
2 and interferon-g, and was followed by a significant
improvement in clinical conditions (reduction of fever, in-
crease in body weight, improvement in radiological findings,
and negativization of M. tuberculosis cultures) in all patients.
Our data, along with the results of Bekker et al., emphasize
the usefulness of thalidomide treatment in patients infected
by M. tuberculosis and demonstrate the complexity of the
immunomodulating effects mediated by this drug. In agree-
ment with the more recent in vivo reports, we confirm that
thalidomide did not reduce TNF-a levels, and this is probably
due to an activation of T cell activity, as hypothesized by
Bekker and colleagues. However, these data raise questions
as to the nature of the interaction between TNF-a and tha-
lidomide. In the light of these results, we suggest extreme
caution in undertaking studies that support the clinical use
of thalidomide, on the basis of the assumption of its contra-
dictory role in TNF-a inhibition.
Andrea Gori,1 Maria Cristina Rossi,1
Daria Trabattoni,2 Giulia Marchetti,1
Maria Luisa Fusi,2 Chiara Molteni,1
Mario Clerici,2 and Fabio Franzetti1
1Institute of Infectious Diseases and Tropical Medicine
and 2Chair of Immunology, “Luigi Sacco” Hospital,
University of Milan, Milan, Italy
References
1. Bekker L-G, Haslett P, Maartens G, Steyn L, Kaplan G. Thalidomide-induced
antigen-specific immune stimulation in patients with human immunodefi-
ciency virus type 1 and tuberculosis. J Infect Dis 2000;181:954–65.
2. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on
the clinical and immunological manifestation of erythema nodosum lepro-
sum. J Infect Dis 1993;168:408–14.
3. Tramontana JM, Utaipat U, Molloy A, et al. Thalidomide treatment reduces
tumor necrosis factor a production and enhances weight gain in patients
with pulmonary tuberculosis. Mol Med 1995;1:384–97.
4. Sampaio EP, Sarno EN, Gallily R, et al. Thalidomide selectively inhibits tumor
necrosis factor a production by stimulated human monocytes. J Exp Med
1991;173:699–703.
5. Haslett PAJ, Corral LG, Albert M, et al. Thalidomide costimulates primary
human T lymphocytes, preferentially inducing proliferation, cytokine pro-
duction, and cytotoxic responses in the CD81 subset. J Exp Med 1998;
187:1885–92.
6. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti–TNF-alpha
inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996;
81:219–23.
7. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of
thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:
1586–9.
8. Jacobson JM, Spritzler J, Fox L, et al. Thalidomide for the treatment of
esophageal aphthous ulcers in patients with human immunodeficiency virus
infection. J Infect Dis 1999;180:61–7.
Financial support: This work was supported in part by a grant from the Italian
National Institute of Health, “National Research Program on AIDS.”
Reprints or correspondence: Dr. Andrea Gori, Institute of Infectious Diseases
and Tropical Medicine, University of Milan, “L. Sacco” Hospital, Via G.B. Gras-
si 74 20157, Milan, Italy (andrea.gori@unimi.it).
The Journal of Infectious Diseases 2000;182:639
q 2000 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2000/18202-0039$02.00
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/182/2/639/2191777 by D
ivisione C
oordinam
ento Biblioteche U
ni M
I user on 19 M
arch 2019
